Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination immune response in PTEN hamartoma tumour syndrome
NL-OMON49354Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen in influenza, sponsored by Radboud University Medical Center. Primary endpoint: Antibody titre concentration by hemagglutination inhibition assay. Started Jul 2021; status: active, not recruiting.
02
Drugs
Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON49354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49354.